TY - JOUR T1 - “Double blind, you are the weakest link — goodbye!” JF - Evidence Based Medicine JO - Evid Based Med SP - 4 LP - 5 DO - 10.1136/ebm.7.1.4 VL - 7 IS - 1 AU - P J Devereaux AU - Mohit Bhandari AU - Victor M Montori AU - Braden J Manns AU - William A Ghali AU - Gordon H Guyatt Y1 - 2002/01/01 UR - http://ebm.bmj.com/content/7/1/4.abstract N2 - Double blind is the term researchers frequently use, and readers frequently accept, as a key marker of validity of a randomised controlled trial (RCT). Clinical trial experts and clinicians, when asked, all claim to “know” what double blind means; however, unfortunately it means diverse things to those questioned.1 The term lacks consistency in its use and interpretation — a critical flaw for any technical term if it is to be understood. In this editorial, we advocate abandoning the current blinding lexicon (ie, single, double, and triple blinding) and recommend transparent reporting of the blinding status of each group involved in the execution, monitoring, and reporting of clinical trials.Blinding (or masking) in RCTs is the process of withholding information about treatment allocation from those who could potentially be influenced by this information. Blinding has long been considered an important safeguard against bias. Benjamin Franklin, in 1784, was probably the first to use blinding in scientific experimentation.2 Louis … ER -